285 related articles for article (PubMed ID: 25131761)
21. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
[TBL] [Abstract][Full Text] [Related]
22. [Genetic alterations and transformations in development and establishment of uterine endometrial carcinomas].
Inoue M
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Aug; 45(8):751-62. PubMed ID: 8371006
[TBL] [Abstract][Full Text] [Related]
23. Expression of type 2 orexin receptor in human endometrium and its epigenetic silencing in endometrial cancer.
Dehan P; Canon C; Trooskens G; Rehli M; Munaut C; Van Criekinge W; Delvenne P
J Clin Endocrinol Metab; 2013 Apr; 98(4):1549-57. PubMed ID: 23482607
[TBL] [Abstract][Full Text] [Related]
24. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer.
Sasaki M; Kaneuchi M; Sakuragi N; Dahiya R
Cancer Res; 2003 Jun; 63(12):3101-6. PubMed ID: 12810635
[TBL] [Abstract][Full Text] [Related]
25. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
Pijnenborg JM; Dam-de Veen GC; Kisters N; Delvoux B; van Engeland M; Herman JG; Groothuis PG
Ann Oncol; 2007 Mar; 18(3):491-7. PubMed ID: 17170014
[TBL] [Abstract][Full Text] [Related]
26. Hypermethylation in the p16 promoter region in the carcinogenesis of endometrial cancer in Japanese patients.
Yanokura M; Banno K; Susumu N; Kawaguchi M; Kuwabara Y; Tsukazaki K; Aoki D
Anticancer Res; 2006; 26(2A):851-6. PubMed ID: 16619479
[TBL] [Abstract][Full Text] [Related]
27. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma.
Pallarés J; Velasco A; Eritja N; Santacana M; Dolcet X; Cuatrecasas M; Palomar-Asenjo V; Catasús L; Prat J; Matias-Guiu X
Mod Pathol; 2008 Jun; 21(6):691-9. PubMed ID: 18469797
[TBL] [Abstract][Full Text] [Related]
28. Molecular and pathologic aspects of endometrial carcinogenesis.
Hecht JL; Mutter GL
J Clin Oncol; 2006 Oct; 24(29):4783-91. PubMed ID: 17028294
[TBL] [Abstract][Full Text] [Related]
29. MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A.
Ye W; Xue J; Zhang Q; Li F; Zhang W; Chen H; Huang Y; Zheng F
Oncol Rep; 2014 Sep; 32(3):1193-9. PubMed ID: 24993091
[TBL] [Abstract][Full Text] [Related]
30. DNA Methylation Machinery in the Endometrium and Endometrial Cancer.
Caplakova V; Babusikova E; Blahovcova E; Balharek T; Zelieskova M; Hatok J
Anticancer Res; 2016 Sep; 36(9):4407-20. PubMed ID: 27630276
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers in the endometrium.
Berchuck A
J Cell Biochem Suppl; 1995; 23():174-8. PubMed ID: 8747393
[TBL] [Abstract][Full Text] [Related]
32. Expression of microRNA Potentially Regulated by AhR and CAR in Malignant Tumors of the Endometrium.
Ushakov DS; Dorozhkova AS; Babayants EV; Ovchinnikov VY; Kushlinskii DN; Adamyan LV; Gulyaeva LF; Kushlinskii NE
Bull Exp Biol Med; 2018 Sep; 165(5):688-691. PubMed ID: 30225717
[TBL] [Abstract][Full Text] [Related]
33. Advances in the molecular genetics of endometrial cancer (Review).
Esteller M; Xercavins J; Reventos J
Oncol Rep; 1999; 6(6):1377-82. PubMed ID: 10523715
[TBL] [Abstract][Full Text] [Related]
34. Importance of promoter methylation of GATA4 and TP53 genes in endometrioid carcinoma of endometrium.
Chmelarova M; Kos S; Dvorakova E; Spacek J; Laco J; Ruszova E; Hrochova K; Palicka V
Clin Chem Lab Med; 2014 Aug; 52(8):1229-34. PubMed ID: 24651021
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic mechanisms in endometrial cancer.
Stampoliou A; Arapantoni-Dadioti P; Pavlakis K
J BUON; 2016; 21(2):301-6. PubMed ID: 27273937
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer.
Huang YW; Liu JC; Deatherage DE; Luo J; Mutch DG; Goodfellow PJ; Miller DS; Huang TH
Cancer Res; 2009 Dec; 69(23):9038-46. PubMed ID: 19887623
[TBL] [Abstract][Full Text] [Related]
37. Molecular genetics and endometrial cancer.
Oehler MK; Brand A; Wain GV
J Br Menopause Soc; 2003 Mar; 9(1):27-31. PubMed ID: 12804310
[TBL] [Abstract][Full Text] [Related]
38. SOX11 hypermethylation as a tumor biomarker in endometrial cancer.
Shan T; Uyar DS; Wang LS; Mutch DG; Huang TH; Rader JS; Sheng X; Huang YW
Biochimie; 2019 Jul; 162():8-14. PubMed ID: 30935961
[TBL] [Abstract][Full Text] [Related]
39. Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development.
Jones A; Teschendorff AE; Li Q; Hayward JD; Kannan A; Mould T; West J; Zikan M; Cibula D; Fiegl H; Lee SH; Wik E; Hadwin R; Arora R; Lemech C; Turunen H; Pakarinen P; Jacobs IJ; Salvesen HB; Bagchi MK; Bagchi IC; Widschwendter M
PLoS Med; 2013 Nov; 10(11):e1001551. PubMed ID: 24265601
[TBL] [Abstract][Full Text] [Related]
40. The Role of KRAS in Endometrial Cancer: A Mini-Review.
Sideris M; Emin EI; Abdullah Z; Hanrahan J; Stefatou KM; Sevas V; Emin E; Hollingworth T; Odejinmi F; Papagrigoriadis S; Vimplis S; Willmott F
Anticancer Res; 2019 Feb; 39(2):533-539. PubMed ID: 30711927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
